Arrowhead reports FY2026 results, highlights REDEMPLO growth and sNDA submissionNov 12Quarterly updateArrowhead Pharmaceuticalsplozasiran
Arrowhead refinances $400 million Sixth Street facility at lower rateNov 4FinancingArrowhead Pharmaceuticals
Arrowhead's ARO-INHBE obesity trial remains active, not recruiting, with 190 enrolledOct 30Trial updateARO-INHBEArrowhead Pharmaceuticals
Arrowhead's two Phase 3 plozasiran SHTG trials both show completed status this weekOct 9Weekly roundup, 4 itemsARO-INHBEArrowhead PharmaceuticalsUpdated
Arrowhead's SHASTA-10 extension study for plozasiran stays active, not recruitingOct 1Trial updateArrowhead Pharmaceuticalsplozasiran
Arrowhead's ARO-MUC5AC trial marked terminated for business reasons; results posted to registrySep 14Trial updateARO-MUC5ACArrowhead Pharmaceuticals
Arrowhead posts Phase 1/2a results for inhaled ARO-MMP7 in IPF trialAug 5Trial updateArrowhead Pharmaceuticals
Arrowhead reports fiscal Q3 2026 results with plozasiran Phase 3 data and Madrigal dealAug 4Quarterly updateArrowhead Pharmaceuticalsplozasiran